Sino Biopharm Buys Back 15.35 Million Shares for HK$89.86 Million, Equal to 0.08% of Issued Capital

Bulletin Express03-30

Sino Biopharmaceutical Limited repurchased a total of 15.35 million shares on 27 and 30 March 2026 via on-market transactions, paying an aggregate HK$89.86 million.

The two tranches were executed as follows: • 27 March 2026: 5.35 million shares at an average HK$5.8762 per share • 30 March 2026: 10 million shares at an average HK$5.8424 per share

The weighted-average repurchase price across both sessions is approximately HK$5.85 per share.

All repurchased shares are intended for cancellation and represent 0.08% of the 18.76 billion shares in issue when the current buy-back mandate was granted on 10 June 2025. Following cancellation, the outstanding share count will decrease accordingly.

Under the existing mandate, the company is authorised to repurchase up to 1.88 billion shares; only 0.82% of this limit has been utilised to date. In line with Hong Kong Stock Exchange rules, Sino Biopharm is subject to a 30-day moratorium on new share issues or treasury-share disposals, ending 29 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment